A Phase 1/1b Study of IAM1363 in Participants With Advanced Cancers Harboring HER2 Alterations
This study is testing a new experimental drug called IAM1363 to see if it is safe and effective for patients with advanced cancers. Researchers are looking specifically at cancers that have a 'HER2' genetic change, which is a protein that can cause cancer cells to grow faster than normal.
This trial is for adults (18+) with advanced cancers—such as breast, lung, bladder, or stomach cancer—that have tested positive for HER2 alterations. To join, your cancer must have worsened after previous treatments or you must be unable to tolerate those standard therapies.
As a participant, you will receive the experimental drug IAM1363 and have your health monitored closely by a medical team. This includes regular check-ups and imaging scans (like CT or MRI) to see how your tumor responds to the treatment.
The study is currently recruiting patients at research centers in La Jolla and Los Angeles, California, and Aurora, Colorado. Please contact your doctor or the study team to see if one of these locations is right for you.
- 1Tests a new medication for cancers with HER2 genetic changes.
- 2Designed to help patients who have already tried other cancer treatments.
- 3Involves close medical supervision to ensure your safety throughout the process.
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.